VanEck Biotech ETFBBH
Type
ETF
Peer group
US equity: Healthcare
Net assets
$371.6M
Expense ratio
0.35%
1-year return
+43.8%
3 years, a year
+13.7%
5 years, a year
+2.3%
12-month yield
0.39%
Holdings
25
What it aims to do.
VanEck Biotech ETF (the Fund) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (the Biotech Index or the Index).
Top 10 holdings.
| Holding | % of fund |
|---|---|
| GILD Gilead Sciences Inc | 14.63% |
| AMGN Amgen Inc | 14.54% |
| VRTX Vertex Pharmaceuticals Inc | 8.06% |
| REGN Regeneron Pharmaceuticals Inc | 7.51% |
| ARGX Argenx SE | 5.28% |
| INSM Insmed Inc | 4.59% |
| IQV IQVIA Holdings Inc | 4.30% |
| ALNY Alnylam Pharmaceuticals Inc | 4.11% |
| NTRA Natera Inc | 3.98% |
| UTHR United Therapeutics Corp | 3.81% |
More on BBH.
- BBH overview
- BBH holdings
- BBH risk
- BBH costs
- BBH money in and out
- BBH share classes
- Compare BBH with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.